AbbVie Reports First|Quarter 2020 Financial Results

AbbVie Reports First-Quarter 2020 Financial Results

AbbVie is updating its standalone GAAP diluted EPS guidance for the full-year 2020 from $7.66 to $7.76 to $7.60 to $7.70, representing growth of 44.9 percent ...

AbbVie Reports First-Quarter 2020 Financial Results - SEC.gov

Reports First-Quarter Diluted EPS of $2.02 on a GAAP Basis; Adjusted Diluted EPS of $2.42 · First-Quarter Net Revenues Were $8.619 Billion, an ...

AbbVie Reports Full-Year and Fourth-Quarter 2020 Financial Results

- Reports Full-Year Diluted EPS of $2.72 on a GAAP Basis; Adjusted Diluted EPS of $10.56 · - Delivers Full-Year Net Revenues of $45.804 Billion ...

AbbVie Reports Second-Quarter 2020 Financial Results

Second-Quarter Net Revenues Were $10.425 Billion, an Increase of 26.3 Percent on a Reported Basis, Inclusive of a Partial Quarter of Allergan and COVID-19 ...

AbbVie Reports Third-Quarter 2020 Financial Results

Delivers third-quarter net revenues of $12.902 billion on a GAAP basis, an increase of 52.1 percent on a reported basis; adjusted net revenues were $12.882 ...

Financial releases - Abbvie Investor Relations

Toggle Summary 10/30/24, AbbVie Reports Third-Quarter 2024 Financial Results.

AbbVie Reports First-Quarter 2021 Financial Results

Financial Release · - Reports First-Quarter Diluted EPS of $1.99 on a GAAP Basis; Adjusted Diluted EPS of $2.95 · - Delivers First-Quarter Net Revenues of $13.010 ...

ImmunoGen Reports Recent Progress and First Quarter 2020 ...

Enyedy added, “Having generated approximately $98M in net proceeds through a follow-on offering in January, we are in a strong financial ...

AbbVie Reports Third-Quarter 2024 Financial Results - PR Newswire

Reports Third-Quarter Diluted EPS of $0.88 on a GAAP Basis, a Decrease of 12.0 Percent; Adjusted Diluted EPS of $3.00, an Increase of 1.7 ...

AbbVie Reports First-Quarter 2023 Financial Results - Stock Titan

AbbVie reported its first-quarter 2023 financial results with a GAAP diluted EPS of $0.13, down 94.8% from the previous year, ...

AbbVie Inc (ABBV) Q1 2020 Earnings Call Transcript | The Motley Fool

Thank you, Mike. Starting with our first quarter results, we delivered strong top-line and bottom-line performance. Total net revenues were $8.6 ...

AbbVie Reports First-Quarter 2021 Financial Results - PR Newswire

Worldwide GAAP net revenues were $13.010 billion, an increase of 51.0 percent on a reported basis. Worldwide adjusted net revenues of $12.935 ...

AbbVie Reports Second-Quarter 2024 Financial Results - BioSpace

Global net revenues from the oncology portfolio were $1.634 billion, an increase of 10.5 percent on a reported basis, or 12.2 percent on an ...

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year ...

Total revenues for the full year 2020 consisted of $368.6 million associated with Ironwood's share of the net profits from the sales of LINZESS ...

AbbVie Reports Full-Year and Fourth-Quarter 2021 Financial Results

Financial Release · - Reports Full-Year Diluted EPS of $6.45 on a GAAP Basis, an Increase of 137.1 Percent; Adjusted Diluted EPS of $12.70, an ...

RON WYDEN, OREGON, CHAIRMAN - Senate Committee on Finance

... quarter-2019-financial- results.htm; 2019: AbbVie Inc., AbbVie Reports Full-Year and Fourth-Quarter 2020 Financial Results, Feb. 3 2021 ...

Document - SEC.gov

Diluted EPS in the fourth quarter was $2.26 on a GAAP basis. Adjusted diluted EPS, excluding specified items, was $3.31. Note ...

Highlights of AbbVie's Q1 2024 financial results - AlphaStreet

Specialty biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) Friday announced first-quarter 2024 financial results, reporting a decline in ...

Annual report & proxy - Abbvie Investor Relations

Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates ...

AbbVie Reports Full-Year and Fourth-Quarter 2019 Financial Results

AbbVie is issuing its adjusted diluted EPS guidance for the full-year 2020 of $9.61 to $9.71, representing growth of 8.1 percent at the midpoint ...